Protocol Ledger

NCT05463744 · Phase III · COMPLETED

A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy

Interventional Phase III clinical trial protocol NCT05463744 sponsored by Eli Lilly and Company in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-08-12 Enrollment: 692 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05463744
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)692 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05463744
Protocol FieldVerified Registry Value
NCT IdentifierNCT05463744
Consolidated Lead SponsorEli Lilly and Company
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment692 participants (ACTUAL)
Registered Start Date2022-08-12
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05463744
Hospital Research SiteLocationSite Profile
Valley ResearchFresno, CAOpen Hospital Dossier ->
Catalina Research Institute, LLCMontclair, CAOpen Hospital Dossier ->
University of Colorado Anschutz Medical CampusAurora, COOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI